Unique Ingredient Identifier 55X04QC32I is listed as a ingredient substance
| RN | 1310-73-2 |
| EC | 215-185-5 |
| NCIT | C74373 |
| RXCUI | 9880 |
| PUBCHEM | 14798 |
| MF | Na.HO |
| INCHI KEY | HEMHJVSKTPXQMS-UHFFFAOYSA-M |
| SMILES | [OH-].[Na+] |
UNII 55X04QC32I SODIUM HYDROXIDE is commonly included in medications in the following forms.
| Route | Dosage Form | Potency |
|---|---|---|
| AN,CNBLK INTRATHECAL | INJECTION | ADJPH |
| AN,INFILTRATION | INJECTABLE | ADJPH |
| AN,INFILTRATION | INJECTION | 0.071 % |
| AN,INFILTRATION | SOLUTION, INJECTION | ADJPH |
| AN,SYMPATHETIC NBLK | INJECTION | ADJPH |
| AURICULAR (OTIC) | SOLUTION | 0.8 % |
| AURICULAR (OTIC) | SOLUTION, DROPS | ADJPH |
| AURICULAR (OTIC) | SUSPENSION | ADJPH |
| BUCCAL | FILM | 0.09 MG |
| BUCCAL | FILM, SOLUBLE | 1.18 MG |
| CAUDAL BLOCK | INJECTABLE | ADJPH |
| CAUDAL BLOCK | INJECTION | ADJPH |
| DENTAL | INJECTABLE | ADJPH |
| DENTAL | INJECTION | ADJPH |
| DENTAL | PASTE | NA |
| DENTAL | SOLUTION | ADJPH |
| EPIDURAL | INJECTION | ADJPH |
| EPIDURAL | INJECTION, SOLUTION | ADJ PH |
| EPIDURAL | LIQUID, WATER, STERILE, FOR INJECTION | ADJPH |
| EPIDURAL | SOLUTION | ADJPH |
| EPIDURAL | SOLUTION, INJECTION | ADJPH |
| EXTRACORPOREAL | INJECTION | ADJPH |
| EXTRACORPOREAL | SOLUTION | ADJPH |
| IM - IV | INJECTABLE | ADJPH |
| IM - IV | INJECTION | 4.2 mg/mL |
| IM - IV | INJECTION | ADJ PH |
| IM - IV | INJECTION | ADJPH |
| IM - IV | INJECTION, SOLUTION | ADJPH |
| IM - IV | LIQUID, WATER, STERILE, FOR INJECTION | ADJPH |
| IM - IV | POWDER | ADJPH |
| IM - IV | POWDER, FOR INJECTION SOLUTION | 0.7 % |
| IM - IV | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | ADJPH |
| IM - IV | SOLUTION, INJECTION | 0.13 % |
| IM - IV - SC | INJECTION | ADJPH |
| IM - IV - SC | POWDER, FOR INJECTION SOLUTION | ADJPH |
| IM - IV - SC | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | ADJPH |
| IM - IV - SC | SOLUTION, INJECTION | ADJPH |
| IM - SC | INJECTION | ADJPH |
| IM - SC | INJECTION, SUSTAINED ACTION | ADJPH |
| IM - SC | POWDER, FOR INJECTION SOLUTION | ADJPH |
| IM, IV | INJECTION | ADJ PH |
| INFILTRATION | INJECTION | ADJPH |
| INFILTRATION | INJECTION, SOLUTION | ADJ PH |
| INFILTRATION | SOLUTION, INJECTION | ADJPH |
| INHALATION | AEROSOL, METERED | ADJPH |
| INHALATION | INHALANT SOLUTION DOSAGE FORM | ADJ PH |
| INHALATION | SOLUTION | 8 % |
| INHALATION | SOLUTION | ADJ PH |
| INJECTION | INJECTABLE | ADJ PH |
| INJECTION | INJECTION | ADJ PH |
| INJECTION | INJECTION, SOLUTION | ADJ PH |
| INTERSTITIAL | INJECTION | ADJPH |
| INTRA-AMNIOTIC | INJECTION | ADJPH |
| INTRA-ARTERIAL | INJECTABLE | 0.44 % |
| INTRA-ARTERIAL | INJECTION | 17.6 % |
| INTRA-ARTERIAL | INJECTION | 4.2 mg/mL |
| INTRA-ARTERIAL | POWDER, FOR INJECTION SOLUTION | ADJPH |
| INTRA-ARTERIAL | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | ADJPH |
| INTRA-ARTERIAL | SOLUTION, INJECTION | ADJPH |
| INTRA-ARTERIAL | SUSPENSION, INJECTION | ADJ PH |
| INTRA-ARTICULAR | INJECTABLE | ADJPH |
| INTRA-ARTICULAR | INJECTION | ADJ PH |
| INTRA-ARTICULAR | INJECTION | ADJPH |
| INTRA-ARTICULAR | INJECTION, SOLUTION | ADJ PH |
| INTRA-ARTICULAR | INJECTION, SUSTAINED ACTION | ADJPH |
| INTRABURSAL | INJECTION | ADJPH |
| INTRACARDIAC | INJECTION | ADJPH |
| INTRACAUDAL | INJECTION | ADJPH |
| INTRACAUDAL | INJECTION, SOLUTION | ADJ PH |
| INTRACAVITARY | INJECTION | ADJPH |
| INTRACAVITARY | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | ADJPH |
| INTRADERMAL | INJECTION | ADJPH |
| INTRADERMAL | INJECTION, SUSTAINED ACTION | ADJPH |
| INTRADERMAL | POWDER, FOR INJECTION SOLUTION | ADJPH |
| INTRADISCAL | POWDER, FOR INJECTION SOLUTION | ADJPH |
| INTRALESIONAL | INJECTABLE | ADJPH |
| INTRALESIONAL | INJECTION | ADJPH |
| INTRALESIONAL | INJECTION, SUSTAINED ACTION | ADJPH |
| INTRALESIONAL | SUSPENSION, INJECTION | ADJPH |
| INTRAMUSCULAR | INJECTABLE | 0.44 %W/V |
| INTRAMUSCULAR | INJECTABLE | ADJ PH |
| INTRAMUSCULAR | INJECTION | 17.6 % |
| INTRAMUSCULAR | INJECTION | 4.2 mg/mL |
| INTRAMUSCULAR | INJECTION | ADJ PH |
| INTRAMUSCULAR | INJECTION, SOLUTION | ADJ PH |
| INTRAMUSCULAR | INJECTION, SOLUTION | ADJPH |
| INTRAMUSCULAR | INJECTION, SUSPENSION | ADJ PH |
| INTRAMUSCULAR | INJECTION, SUSTAINED ACTION | ADJPH |
| INTRAMUSCULAR | LIQUID | ADJPH |
| INTRAMUSCULAR | POWDER, FOR INJECTION SOLUTION | ADJPH |
| INTRAMUSCULAR | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | 0.35 %W/V |
| INTRAMUSCULAR | SOLUTION | ADJPH |
| INTRAMUSCULAR | SOLUTION, INJECTION | 0.1 %W/V |
| INTRAMUSCULAR | SUSPENSION, EXTENDED RELEASE | ADJPH |
| INTRAMUSCULAR | SUSPENSION, INJECTION | 0.43 % |
| INTRAOCULAR | SOLUTION | ADJPH |
| INTRAPERITONEAL | INJECTION | ADJPH |
| INTRAPERITONEAL | SOLUTION | ADJPH |
| INTRAPLEURAL | INJECTION | ADJPH |
| INTRASPINAL | INJECTION | ADJPH |
| INTRASYNOVIAL | INJECTABLE | ADJPH |
| INTRASYNOVIAL | INJECTION | ADJPH |
| INTRASYNOVIAL | INJECTION, SUSTAINED ACTION | ADJPH |
| INTRASYNOVIAL | SUSPENSION, INJECTION | ADJPH |
| INTRATHECAL | INJECTABLE | 0.44 % |
| INTRATHECAL | INJECTION | 17.6 % |
| INTRATHECAL | INJECTION | 4.2 mg/mL |
| INTRATHECAL | INJECTION, SOLUTION | ADJ PH |
| INTRATHECAL | POWDER, FOR INJECTION SOLUTION | ADJPH |
| INTRATHECAL | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | ADJPH |
| INTRATHECAL | SOLUTION | ADJPH |
| INTRATHECAL | SOLUTION, INJECTION | ADJPH |
| INTRATRACHEAL | INJECTION | NA |
| INTRATRACHEAL | POWDER, FOR SUSPENSION | ADJPH |
| INTRATRACHEAL | SUSPENSION | ADJPH |
| INTRATUMOR | INJECTABLE | ADJPH |
| INTRATUMOR | INJECTION | ADJPH |
| INTRATUMOR | POWDER, FOR INJECTION SOLUTION | ADJPH |
| INTRAUTERINE | INJECTION | ADJPH |
| INTRAVASCULAR | INJECTION | ADJPH |
| INTRAVASCULAR | SOLUTION | ADJPH |
| INTRAVASCULAR | SOLUTION, INJECTION | ADJPH |
| INTRAVENOUS | EMULSION, INJECTION | ADJ PH |
| INTRAVENOUS | EMULSION, INJECTION | ADJPH |
| INTRAVENOUS | INJECTABLE | 0.6 % |
| INTRAVENOUS | INJECTABLE | ADJ PH |
| INTRAVENOUS | INJECTION | 11.6 MG/VIAL |
| INTRAVENOUS | INJECTION | 9.6 % |
| INTRAVENOUS | INJECTION | 4.2 mg/40mL |
| INTRAVENOUS | INJECTION | 0.64 MG/1ML |
| INTRAVENOUS | INJECTION | ADJ PH |
| INTRAVENOUS | INJECTION | ADH PH |
| INTRAVENOUS | INJECTION | QS |
| INTRAVENOUS | INJECTION | ADJPH |
| INTRAVENOUS | INJECTION, EMULSION | ADJ PH |
| INTRAVENOUS | INJECTION, POWDER, LYOPHILIZED, FOR LIPOSOMAL SUSP | ADJPH |
| INTRAVENOUS | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | ADJPH |
| INTRAVENOUS | INJECTION, SOLUTION | 1.2 mg/1mL |
| INTRAVENOUS | INJECTION, SOLUTION | ADJ PH |
| INTRAVENOUS | INJECTION, SOLUTION | QS |
| INTRAVENOUS | INJECTION, SOLUTION | ADJPH |
| INTRAVENOUS | INJECTION, SUSPENSION | ADJPH |
| INTRAVENOUS | INJECTION, SUSPENSION, LIPOSOMAL | ADJPH |
| INTRAVENOUS | LIQUID | ADJPH |
| INTRAVENOUS | LIQUID | ADJ PH |
| INTRAVENOUS | LIQUID, WATER, STERILE, FOR INJECTION | ADJPH |
| INTRAVENOUS | POWDER | ADJPH |
| INTRAVENOUS | POWDER FOR INJECTION DOSAGE FORM | ADJ PH |
| INTRAVENOUS | POWDER, FOR INJECTION SOLUTION | 22 mg/1VIAL |
| INTRAVENOUS | POWDER, FOR INJECTION SOLUTION | 13.66 % |
| INTRAVENOUS | POWDER, FOR INJECTION SOLUTION | ADJ PH |
| INTRAVENOUS | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | 78.36 MG/1VIAL |
| INTRAVENOUS | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | 19.27 % |
| INTRAVENOUS | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | 11.6 MG/VIAL |
| INTRAVENOUS | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | ADJ PH |
| INTRAVENOUS | SOLUTION | ADJ PH |
| INTRAVENOUS | SOLUTION | ADJPH |
| INTRAVENOUS | SOLUTION, CONCENTRATE | ADJPH |
| INTRAVENOUS | SOLUTION, INJECTION | 0.1 % |
| INTRAVENOUS | SOLUTION, LIPOSOME, INJECTION | ADJPH |
| INTRAVENOUS | SOLUTION, LIQUID | ADJ PH |
| INTRAVENOUS INFUSION | INJECTABLE | ADJ PH |
| INTRAVENOUS INFUSION | INJECTION | 0.12 % |
| INTRAVENOUS INFUSION | INJECTION | ADJ PH |
| INTRAVENOUS INFUSION | POWDER | ADJ PH |
| INTRAVESICAL | SOLUTION, INJECTION | ADJPH |
| INTRAVITREAL | INJECTABLE | ADJPH |
| INTRAVITREAL | INJECTION | ADJPH |
| INTRAVITREAL | SUSPENSION, INJECTION | ADJPH |
| IONTOPHORESIS | DRUG DELIVERY SYSTEM | 4.2 MG |
| IONTOPHORESIS | SOLUTION | ADJPH |
| IRRIGATION | SOLUTION | ADJPH |
| IRRIGATION | SOLUTION, IRRIGATION | ADJPH |
| IV - SC | INJECTION | ADJPH |
| IV - SC | POWDER, FOR INJECTION SOLUTION | ADJPH |
| IV - SC | SOLUTION, INJECTION | ADJPH |
| IV(INFUSION) | EMULSION, INJECTION | ADJPH |
| IV(INFUSION) | INFUSION | ADJPH |
| IV(INFUSION) | INJECTABLE | ADJPH |
| IV(INFUSION) | INJECTION | ADJPH |
| IV(INFUSION) | INJECTION, LIPOSOMAL | ADJPH |
| IV(INFUSION) | LIQUID, WATER, STERILE, FOR INJECTION | ADJPH |
| IV(INFUSION) | POWDER, FOR INJECTION SOLUTION | 9 % |
| IV(INFUSION) | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | 1.57 % |
| IV(INFUSION) | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | ADJ PH |
| IV(INFUSION) | SOLUTION | 2.78 % |
| IV(INFUSION) | SOLUTION, INJECTION | 2.83 % |
| NASAL | SOLUTION | ADJPH |
| NASAL | SOLUTION, FOR INHALATION | ADJPH |
| NASAL | SOLUTION, SPRAY | ADJPH |
| NASAL | SPRAY | ADJPH |
| NASAL | SPRAY, METERED | 0.004 % |
| NERVE BLOCK | INJECTABLE | ADJPH |
| NERVE BLOCK | INJECTION | 0.071 % |
| NERVE BLOCK | SOLUTION, INJECTION | ADJPH |
| OPHTHALMIC | DROPS | NA |
| OPHTHALMIC | EMULSION | 0.4 %W/W |
| OPHTHALMIC | EMULSION | ADJ PH |
| OPHTHALMIC | GEL | 1.69 % |
| OPHTHALMIC | POWDER, FOR SOLUTION | ADJPH |
| OPHTHALMIC | SOLUTION | 0.59 % |
| OPHTHALMIC | SOLUTION | 0.53 MG/1ML |
| OPHTHALMIC | SOLUTION | ADJ PH |
| OPHTHALMIC | SOLUTION, DROPS | 0.1 % |
| OPHTHALMIC | SOLUTION, DROPS | ADJ PH |
| OPHTHALMIC | SOLUTION, IRRIGATION | ADJPH |
| OPHTHALMIC | SOLUTION/ DROPS | ADJ PH |
| OPHTHALMIC | SOLUTION/DROPS | ADJPH |
| OPHTHALMIC | SUSPENSION | ADJPH |
| OPHTHALMIC | SUSPENSION, DROPS | ADJPH |
| ORAL | CAPSULE | 9.88 MG |
| ORAL | CAPSULE | ADJ PH |
| ORAL | CAPSULE, COATED | 0.08 MG |
| ORAL | CAPSULE, COATED PELLETS | 0.013 MG |
| ORAL | CAPSULE, DELAYED ACTION | 0.25 MG |
| ORAL | CAPSULE, ENTERIC COATED PELLETS | 0.083 MG |
| ORAL | CAPSULE, SOFT GELATIN LIQUID-FILLED | 1.5 MG |
| ORAL | CONCENTRATE | 10 MG/5ML |
| ORAL | EMULSION | ADJPH |
| ORAL | FILM, SOLUBLE | 1.84 MG |
| ORAL | GRANULE, FOR ORAL SUSPENSION | ADJPH |
| ORAL | LIQUID | 2 MG/5ML |
| ORAL | LIQUID | ADJ PH |
| ORAL | POWDER, FOR ORAL SUSPENSION | 1.7 MG/50ML |
| ORAL | POWDER, FOR SOLUTION | ADJPH |
| ORAL | SOLUTION | 80 MG/1ML |
| ORAL | SOLUTION | 4.56 G/160 mL |
| ORAL | SOLUTION | 4.5 MG/5ML |
| ORAL | SOLUTION, ELIXIR | ADJPH |
| ORAL | SOLUTION, INJECTION | ADJPH |
| ORAL | SUSPENSION | 8 % |
| ORAL | SYRUP | 71 MG/5ML |
| ORAL | TABLET | 7 MG |
| ORAL | TABLET, COATED | NA |
| ORAL | TABLET, DELAYED ACTION | 1.24 MG |
| ORAL | TABLET, DELAYED ACTION, ENTERIC COATED | 0.32 MG |
| ORAL | TABLET, DELAYED RELEASE | 0.1 MG |
| ORAL | TABLET, EXTENDED RELEASE | 5.33 MG |
| ORAL | TABLET, ORALLY DISINTEGRATING | 0.16 MG |
| ORAL | TABLET, SUSTAINED ACTION | 0.4 MG |
| OTIC | SUSPENSION | ADJPH |
| PARENTERAL | INJECTION | ADJPH |
| PARENTERAL | LIQUID, WATER, STERILE, FOR INJECTION | ADJPH |
| PARENTERAL | POWDER, FOR INJECTION SOLUTION | ADJPH |
| PERFUSION, CARDIAC | SOLUTION | ADJPH |
| PERIDURAL | INJECTION | ADJPH |
| PERINEURAL | INJECTION | ADJPH |
| PHOTOPHERESIS | SOLUTION | ADJPH |
| RECTAL | ENEMA | 0.44 % |
| RECTAL | POWDER, FOR INJECTION SOLUTION | ADJPH |
| RECTAL | SOLUTION | 0.63 % |
| RESPIRATORY (INHALATION) | POWDER, FOR INHALATION | ADJPH |
| RESPIRATORY (INHALATION) | SOLUTION | ADJPH |
| RESPIRATORY (INHALATION) | SOLUTION, AEROSOL, FOR INHALATION | ADJPH |
| RESPIRATORY (INHALATION) | SOLUTION, FOR INHALATION | 0.058 % |
| RESPIRATORY (INHALATION) | SOLUTION, INJECTION | ADJPH |
| RETROBULBAR | INJECTION | ADJPH |
| SOFT TISSUE | INJECTABLE | ADJPH |
| SOFT TISSUE | INJECTION | ADJPH |
| SOFT TISSUE | INJECTION, SUSTAINED ACTION | ADJPH |
| SOFT TISSUE | SUSPENSION, INJECTION | ADJPH |
| SPINAL | INJECTABLE | ADJPH |
| SPINAL | INJECTION | ADJPH |
| SUBARACHNOID | SOLUTION, INJECTION | ADJPH |
| SUBCONJUNCTIVAL | INJECTION | ADJPH |
| SUBCUTANEOUS | INJECTABLE | 0.42 % |
| SUBCUTANEOUS | INJECTION | 3.15 % |
| SUBCUTANEOUS | INJECTION | ADJ PH |
| SUBCUTANEOUS | INJECTION, SOLUTION | ADJ PH |
| SUBCUTANEOUS | INJECTION, SOLUTION | ADJPH |
| SUBCUTANEOUS | POWDER, FOR INJECTION SOLUTION | ADJPH |
| SUBCUTANEOUS | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | ADJPH |
| SUBCUTANEOUS | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED, WITH | ADJPH |
| SUBCUTANEOUS | SOLUTION | ADJ PH |
| SUBCUTANEOUS | SOLUTION, INJECTION | 1 % |
| SUBCUTANEOUS | SUSPENSION | ADJPH |
| SUBCUTANEOUS | SUSPENSION, INJECTION | 0.073 % |
| SUBMUCOSAL | INJECTION | ADJPH |
| SUBMUCOSAL | SOLUTION, INJECTION | ADJPH |
| TOPICAL | CREAM | 0.55 %W/W |
| TOPICAL | CREAM, AUGMENTED | 2.72 %W/V |
| TOPICAL | CREAM, EMULSION, SUSTAINED RELEASE | 2.72 %W/V |
| TOPICAL | DISC | NA |
| TOPICAL | EMULSION | 0.2 %W/W |
| TOPICAL | EMULSION, AEROSOL FOAM | ADJPH |
| TOPICAL | EMULSION, CREAM | 0.52 %W/W |
| TOPICAL | EMULSION, CREAM | ADJ PH |
| TOPICAL | EMULSION, LOTION | 0.022 %W/W |
| TOPICAL | GEL | 3.2 %W/W |
| TOPICAL | GEL | 0.0684 ADJ PH |
| TOPICAL | JELLY | NA |
| TOPICAL | LOTION | 2.6 %W/W |
| TOPICAL | LOTION | ADJ PH |
| TOPICAL | LOTION, AUGMENTED | NA |
| TOPICAL | OINTMENT | NA |
| TOPICAL | OINTMENT, AUGMENTED | 0.11 %W/W |
| TOPICAL | SHAMPOO | NA |
| TOPICAL | SOLUTION | 0.59 %W/V |
| TOPICAL | SOLUTION | 0.002 MG/1ML |
| TOPICAL | SOLUTION | ADJ PH |
| TOPICAL | SOLUTION, DROPS | ADJPH |
| TOPICAL | SOLUTION/DROPS | NA |
| TOPICAL | SPONGE | NA |
| TOPICAL | SUSPENSION | NA |
| TOPICAL | SUSPENSION, DROPS | NA |
| TOPICAL | SWAB | ADJPH |
| TRANSDERMAL | DRUG DELIVERY SYSTEM | 4.2 MG |
| TRANSDERMAL | FILM, CONTROLLED RELEASE | 0.85 MG |
| TRANSDERMAL | GEL | 4.72 % |
| TRANSDERMAL | GEL | ADJ PH |
| TRANSDERMAL | GEL, METERED | 7 % |
| URETERAL | SOLUTION | ADJPH |
| URETHRAL | SOLUTION | ADJPH |
| VAGINAL | CREAM, EMULSION, SUSTAINED RELEASE | 0.025 % |
| VAGINAL | EMULSION, CREAM | 0.19 % |
| VAGINAL | GEL | 0.25 % |